The success of mRNA vaccines during the COVID-19 pandemic placed lipid nanoparticle formulation at the center of modern drug delivery science. Yet the technology behind LNPs extends far beyond vaccines — these delivery vehicles are now central to gene therapy, siRNA therapeutics, base editing, and protein replacement strategies. Getting the formulation right demands a precise understanding of each lipid component, their molar ratios, and the process parameters that govern particle assembly.
This guide consolidates everything you need to design, optimize, and characterize LNP formulations, with particular attention to the role of PEG-lipids — the component that most directly determines particle size, stability, and pharmacokinetic behavior.
What Are Lipid Nanoparticles?
Lipid nanoparticles are spherical delivery vehicles typically 50–200 nm in diameter, composed of a lipid mixture that self-assembles around nucleic acid cargo during rapid mixing of an ethanol-lipid phase with an acidic aqueous phase. Unlike traditional liposomes, which feature a defined aqueous interior surrounded by a lipid bilayer, LNPs exhibit a more complex internal architecture — an electron-dense core of inverted hexagonal lipid phases interspersed with nucleic acid.
This structural distinction matters. The inverted hexagonal phase is what enables efficient endosomal escape after cellular uptake, a property critical to therapeutic efficacy. The external surface, meanwhile, is defined primarily by the PEG-lipid corona, which governs interactions with biological fluids, opsonization rates, and circulation half-life.
LNPs gained regulatory validation with the approval of patisiran (Onpattro®) in 2018 for siRNA delivery and were subsequently used in both the Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines. The formulation principles underlying these products now serve as the starting point for hundreds of clinical and preclinical programs.
The Four Core Components of an LNP
Every LNP formulation is built from four classes of lipid, each performing a distinct function. The standard molar ratio — roughly 50:10:38.5:1.5 (ionizable lipid : helper lipid : cholesterol : PEG-lipid) — serves as a widely used starting point, though optimal ratios vary by cargo type and target tissue.
Ionizable Lipids (40–50 mol%)
Ionizable lipids are the functional engine of the LNP. At acidic pH (below their pKa, typically 6.0–6.5), they carry a positive charge that enables electrostatic complexation with negatively charged nucleic acids. At physiological pH 7.4, they become neutral, reducing toxicity and immune activation during circulation.
Upon endocytic uptake, the drop in endosomal pH re-protonates the ionizable lipid, driving interaction with the anionic endosomal membrane and facilitating cargo release into the cytoplasm. The chemical structure of the ionizable lipid — particularly its headgroup geometry, linker chemistry, and tail saturation — profoundly affects transfection efficiency.
Notable ionizable lipids include DLin-MC3-DMA (used in Onpattro), SM-102 (Moderna), and ALC-0315 (Pfizer-BioNTech). For a deeper exploration of how ionizable lipids and PEG-lipids work together, see our article on ionizable lipids vs PEG-lipids in LNP design.
Helper Lipids (10–20 mol%)
Helper lipids such as DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine) or DOPE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine) contribute structural integrity to the nanoparticle. DSPC provides bilayer rigidity owing to its saturated acyl chains, while DOPE’s unsaturated chains promote hexagonal phase formation, which may enhance endosomal escape.
The choice between DSPC and DOPE is not trivial. DOPE-containing formulations often show higher transfection in vitro but may exhibit reduced stability. DSPC-based LNPs tend to be more robust for in vivo applications requiring extended circulation.
Cholesterol (35–45 mol%)
Cholesterol fills molecular gaps between lipid acyl chains, reducing membrane permeability and improving the mechanical stability of the nanoparticle. It also influences membrane fluidity and can modulate the rate of PEG-lipid desorption from the particle surface.
Recent work has explored cholesterol analogs — β-sitosterol, for instance — that can alter internal LNP morphology and improve mRNA delivery to specific cell types. Cholesterol content above 40 mol% generally increases particle stability but may reduce encapsulation efficiency if the formulation becomes too rigid.
PEG-Lipids (1–5 mol%)
PEG-lipids occupy the outermost layer of the LNP, creating a hydrophilic brush or mushroom-like polymer corona that dictates the particle’s behavior in biological environments. Despite comprising the smallest molar fraction, PEG-lipids exert an outsized influence on particle size, polydispersity, circulation time, and cellular uptake.
The PEG-lipid is the component where raw material quality has the most measurable impact on batch-to-batch consistency. For a detailed primer on PEG-lipid chemistry, see our overview on PEG-lipids explained.
The Role of PEG-Lipids in LNP Formulation
PEG-lipids perform three essential functions in lipid nanoparticle formulation:
Steric Stabilization and Size Control
During nanoprecipitation, PEG-lipids migrate to the particle surface and arrest lipid coalescence once they reach sufficient surface density. Higher PEG-lipid molar ratios produce smaller particles; lower ratios yield larger ones. A typical range of 0.5–5 mol% PEG-lipid produces particles from ~120 nm down to ~50 nm, respectively.
The PEG chain length matters as much as the molar ratio. Shorter chains (PEG12, ~530 Da) provide less steric coverage per molecule, while longer chains (PEG45, ~2000 Da) create denser polymer brushes at equivalent molar percentages. We cover this in detail in our article on LNP size optimization through PEG-lipid ratio.
Circulation Half-Life (the “Stealth” Effect)
The PEG corona reduces opsonin adsorption and delays recognition by mononuclear phagocytes, extending circulation time. This stealth effect is critical for applications requiring systemic distribution — extravasation into tumors via the EPR effect, for instance, or delivery to extrahepatic tissues.
However, more PEG is not always better. Excessive PEG density can inhibit cellular uptake by target cells, creating the so-called “PEG dilemma.” Formulations must balance stealth properties against transfection efficiency.
PEG Shedding and the Lipid Anchor
The rate at which PEG-lipid desorbs from the LNP surface after injection — PEG shedding — is governed by the hydrophobic anchor. C14 acyl chains (as in DMG-PEG) shed within hours, enabling efficient cellular uptake at the target site. C18 anchors (as in DSPE-PEG) are much more persistent, maintaining stealth properties for longer but potentially reducing transfection.
For most mRNA and siRNA applications targeting the liver, C14-anchored PEG-lipids such as DMG-PEG24 or DMG-PEG45 are the standard choice. For applications requiring extended circulation — such as tumor targeting or pulmonary delivery — DSPE-anchored variants like mPEG44-DSPE offer the necessary persistence.
For guidance on selecting between these options, see our guide on choosing the right PEG-lipid.
PurePeg offers a full catalog of monodisperse PEG-lipids — 39 products spanning DMG-PEG, DSPE-PEG, and DSG-PEG chemistries — all with defined molecular weights and ≥95% purity, eliminating the batch variability common with polydisperse alternatives. For a ranked comparison, see our article on the top 5 PEG lipids for LNP formulation.
Formulation Parameters and Process Variables
Lipid Molar Ratios
The molar ratio of the four lipid components is the single most important formulation variable. The standard 50:10:38.5:1.5 ratio (ionizable : helper : cholesterol : PEG-lipid) serves as a starting point, but optimization requires systematic variation.
Key relationships: – Ionizable lipid fraction primarily governs encapsulation efficiency and transfection potency – PEG-lipid fraction controls particle size and polydispersity (the most sensitive lever for size tuning) – Cholesterol modulates stability and membrane rigidity – Helper lipid influences internal morphology and endosomal escape
N/P Ratio
The nitrogen-to-phosphate (N/P) ratio describes the charge ratio between ionizable lipid amine groups and nucleic acid phosphate groups. Typical N/P ratios range from 3:1 to 10:1, with 6:1 being common for mRNA formulations. Higher N/P ratios improve encapsulation but may increase toxicity; lower ratios risk incomplete cargo loading.
Mixing Parameters
LNPs are typically prepared by rapid mixing of an ethanol phase (containing dissolved lipids) with an aqueous phase (containing nucleic acid in acidic buffer, pH 4.0–5.0) using either T-junction mixing, microfluidic devices (e.g., NanoAssemblr), or impingement jet mixers.
Critical mixing variables include: – Flow rate ratio (FRR): Aqueous-to-ethanol ratios of 3:1 to 5:1 are standard. Higher FRR generally produces smaller particles. – Total flow rate (TFR): Higher TFR increases mixing efficiency, reducing polydispersity. – Buffer pH: Must be below the ionizable lipid pKa to ensure positive charge for nucleic acid complexation.
Post-Mixing Processing
After initial mixing, formulations are: 1. Diluted to reduce ethanol concentration below 25% 2. Dialyzed or diafiltered against neutral buffer (pH 7.4) to remove ethanol and raise pH, neutralizing the ionizable lipid 3. Concentrated via tangential flow filtration (TFF) to the target concentration 4. Optionally sterile filtered (0.2 μm) — feasible only for particles <100 nm with narrow size distribution
LNP Characterization Methods
Robust characterization is essential for formulation development and regulatory filings. We address this topic comprehensively in our article on 8 critical quality attributes for LNP manufacturing.
Particle Size and Polydispersity
Dynamic light scattering (DLS) is the standard method for measuring hydrodynamic diameter and polydispersity index (PDI). Target specifications are typically 60–100 nm with PDI < 0.2. Nanoparticle tracking analysis (NTA) provides orthogonal sizing with number-weighted distributions.
Encapsulation Efficiency
RiboGreen assay (or PicoGreen for DNA) measures the fraction of nucleic acid entrapped within the LNP versus free in solution. Acceptable encapsulation efficiency is generally >85%, with optimized formulations reaching >95%.
Zeta Potential
Surface charge, measured by electrophoretic light scattering, should be near-neutral at pH 7.4 (typically −5 to +5 mV), confirming that the ionizable lipid is uncharged in circulation. Positive zeta potential at pH 7.4 suggests incomplete neutralization and potential toxicity.
Lipid Composition
Reverse-phase HPLC or LC-MS confirms the molar ratio of each lipid component. This is particularly important for PEG-lipid content, since deviations from the target ratio directly affect particle size and stability. Monodisperse PEG-lipid reagents simplify these assays by providing a single, sharp chromatographic peak rather than the broad distributions seen with polydisperse materials.
Applications of LNP Technology
mRNA Vaccines and Therapeutics
The most validated application. LNPs deliver mRNA encoding viral antigens (vaccines) or therapeutic proteins (enzyme replacement, immunotherapy). Intramuscular injection targets local dendritic cells and myocytes, while intravenous administration is used for liver-directed therapies.
siRNA Therapeutics
Onpattro demonstrated that LNPs can deliver siRNA to hepatocytes with sufficient potency to achieve >80% target gene knockdown. The field is now pursuing extrahepatic siRNA delivery — to the lungs, CNS, and tumors — which demands different PEG-lipid strategies and targeting ligands.
Gene Editing (CRISPR/Cas9)
LNPs can co-encapsulate Cas9 mRNA and guide RNA, or deliver ribonucleoprotein (RNP) complexes directly. The transient expression profile of LNP-delivered mRNA is advantageous for gene editing, minimizing off-target activity compared to viral vectors.
Base Editing and Prime Editing
Next-generation editing technologies require delivery of large mRNA constructs (>4,500 nt for base editors). LNP formulation optimization — particularly the N/P ratio and ionizable lipid selection — becomes critical for efficient encapsulation and delivery of these larger payloads.
For more on LNP applications in drug delivery, see our article on LNPs for drug delivery.
Optimizing Your LNP Formulation
Optimization is inherently iterative. A structured approach accelerates convergence:
Step 1: Define Your Target Product Profile
Specify the target particle size, PDI, encapsulation efficiency, and cargo type. These specifications constrain the design space.
Step 2: Screen Ionizable Lipids
If using a proprietary ionizable lipid library, screen 3–5 candidates at the standard molar ratio. Rank by encapsulation efficiency and in vitro transfection.
Step 3: Optimize PEG-Lipid Selection and Ratio
This is where most formulation refinement occurs. Systematically vary: – PEG-lipid molar fraction (0.5%, 1%, 1.5%, 2%, 3%, 5%) – PEG chain length (PEG12, PEG24, PEG36, PEG45) – Lipid anchor (C14 DMG vs C18 DSPE)
Use DLS to track size and PDI. PurePeg’s monodisperse DMG-PEG series — DMG-PEG24, DMG-PEG36, and DMG-PEG45 — enables precise comparison across chain lengths without the confounding variable of polydispersity.
Step 4: Fine-Tune Process Parameters
Optimize FRR, TFR, and buffer pH. Consider design-of-experiments (DoE) approaches to map the interaction between formulation and process variables.
Step 5: Stability Assessment
Conduct accelerated and real-time stability studies. Monitor size, PDI, encapsulation efficiency, and potency over time. We provide a detailed stability testing protocol in our guide to LNP stability testing.
Step 6: In Vivo Evaluation
Screen lead candidates in animal models, assessing biodistribution, expression kinetics, immunogenicity, and tolerability.
Scaling LNP Formulations from Bench to Manufacturing
The transition from microfluidic bench-scale preparation to clinical and commercial manufacturing introduces challenges that intersect directly with formulation design.
Mixing Platform Differences
Bench-scale LNPs are typically prepared on microfluidic devices (NanoAssemblr Spark or Ignite) with total flow rates of 1–20 mL/min. Clinical-scale production uses impingement jet mixers or T-junction mixers at flow rates of 100–5,000 mL/min. The change in mixing dynamics can shift particle size by 10–30 nm, requiring re-optimization of PEG-lipid molar ratio at each scale.
Downstream Processing
Tangential flow filtration (TFF) for buffer exchange and concentration becomes more critical at scale. The TFF membrane, transmembrane pressure, and number of diavolumes can all affect the final PEG-lipid content — some PEG-lipid may partition into the permeate during diafiltration, effectively reducing the surface PEG density. Monitoring PEG-lipid content before and after TFF is essential.
Raw Material Qualification
At GMP scale, raw material consistency becomes paramount. Lot-to-lot variability in any lipid component translates directly to variability in the final product. This is where monodisperse PEG-lipids provide the most tangible manufacturing advantage: every lot has the same molecular weight, the same HPLC profile, and the same surface activity. There is no need to qualify each new lot against the previous one for chain length distribution — a significant reduction in incoming QC burden.
Frequently Asked Questions
What is the standard lipid molar ratio for LNP formulation?
The most commonly cited starting ratio is 50:10:38.5:1.5 (ionizable lipid : DSPC : cholesterol : PEG-lipid), based on the Onpattro formulation. However, optimal ratios vary by ionizable lipid chemistry and cargo type. mRNA vaccines, for instance, may use slightly different ratios than siRNA formulations.
Why does PEG-lipid purity matter for LNP consistency?
Polydisperse PEG-lipids contain a distribution of PEG chain lengths, which introduces variability in surface PEG density, particle size, and shedding kinetics from batch to batch. Monodisperse PEG-lipids, where every molecule has the same defined chain length, eliminate this variable and improve reproducibility — a critical consideration for GMP manufacturing and regulatory submissions.
How do I choose between DMG-PEG and DSPE-PEG for my formulation?
The choice depends on your target tissue and desired circulation time. DMG-PEG (C14 anchor) sheds from the LNP surface within hours, making it ideal for liver-targeted delivery where rapid cellular uptake is desired. DSPE-PEG (C18 anchor) is more persistent, extending circulation for applications requiring systemic exposure or accumulation in non-liver tissues.
Can LNPs deliver payloads other than mRNA?
Yes. LNPs have been used to deliver siRNA (Onpattro), antisense oligonucleotides, plasmid DNA, mRNA, self-amplifying RNA, guide RNA, and CRISPR ribonucleoprotein complexes. Formulation parameters — particularly the N/P ratio and ionizable lipid selection — must be adjusted for each cargo type.
What particle size should I target for my LNP formulation?
For systemic liver delivery, 60–80 nm is optimal — small enough for hepatic fenestrae penetration while maintaining sufficient cargo capacity. For intramuscular vaccination, 80–120 nm particles are typical. Pulmonary delivery via nebulization may favor smaller particles (<100 nm) to ensure efficient aerosolization.
Looking for monodisperse PEG-lipids for your LNP formulation? Explore PurePeg’s complete PEG-Lipid catalog — 39 products with defined molecular weights and ≥95% purity. Contact our PEG experts or call 1-888-331-8188 to discuss your formulation needs.